Thiotepa
- Generic Name
- Thiotepa
- Brand Names
- Tepadina, Thiotepa Riemser
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N3PS
- CAS Number
- 52-24-4
- Unique Ingredient Identifier
- 905Z5W3GKH
- Background
N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. It...
- Indication
ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.
- Associated Conditions
- Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion
- Associated Therapies
- -
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT00003194
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-05-14
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00027937
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT00003273
- Locations
- 🇺🇸
Cancer Research Center of Hawaii, Honolulu, Hawaii, United States
🇺🇸State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States
🇺🇸Maine Children's Cancer Program, Scarborough, Maine, United States
Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-02-14
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 104
- Registration Number
- NCT00047320
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Nemours Children's Clinic, Jacksonville, Florida, United States
Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-12-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00028730
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Herbert Irving Comprehensive Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00007982
- Locations
- 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases
- Conditions
- Interventions
- First Posted Date
- 2002-06-07
- Last Posted Date
- 2012-08-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT00038857
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.